Platform scaling, but near-term dilution from new acquisitions

USD 30 million fresh equity, US FDA approval July 2026, but unprofitable in FY27; management expects path to profitability FY28–29.

Raised from 70% to majority acquisition planned; digital pathology for 300+ slides/day, early losses but strategic fit.

₹200 Cr total (₹72 Cr automation + ₹105+ Cr R&D centre in Bangalore); will pressure cash flow and near-term ROE.

HPV validation completed by Government of India (AIMS + WHO, Gates Foundation partners). WHO prequalification in progress. Rollout 'soon' post-approvals; specifics deferred to next quarter.

Early installations (2017–18) still running 6–7 years later; no replacements yet. Design for ruggedness; no foreseeable replacement cycle.

R&D 5–6% of revenue (ongoing). CapEx ₹200 Cr: ₹72 Cr automation, ₹105+ Cr R&D centre in Bangalore. No major manufacturing facility expansion needed.

Q1: Molbio ₹399 Cr, Prognosys ₹11 Cr, OptraScan negligible. Prognosys: ₹154 Cr full year last year, ~12 Cr PAT (8% margin). OptraScan losses; profit expected FY28–29.

Historical range 2,200–2,600 units/year. Linear, not seasonal. Expect in-line with historical, but not quarter-on-quarter forecast (Q4 typically strongest).

Very clear mandate globally to transition from smear microscopy to molecular. WHO endorsed Truenat point-of-care only option. Market shift underway; 8K of 25K–30K centres have Truenat. Still long pathway.

Focus on infectious disease + non-communicable. R&D ongoing; specific platform timelines deferred to future calls. HPV and hepatitis are prioritized.

Platforms in development; no specific disease mix or revenue target disclosed. R&D constant, results emerge over time. Not guiding on exact platform rollouts.

Export business 3 years old, 16% of Q1 (₹67 Cr). 90+ countries, registrations ongoing. Stabilizing now; expect 'very important driver' of growth post-FY27. No volume target.

EU IVDR certification received for CT/NG (Chlamydia/Gonorrhoeae). No centralized vs. point-of-care testing conflict; Truenat is decentralized point-of-care, most suitable for places without infrastructure.

HPV study completed, now in WHO prequalification. Specifics deferred to next quarter when clarity on program roll-out available. Still 'long-term process'.

Two-year TB rate contract just signed (last month). Valid for next two years. Government transition underway from microscopy to molecular; Truenat positioned for scale.

No prior FY27 guidance to anchor. Implies ~₹510 Cr full year. Management cited growth target is 'roughly about 25%'.

Q1 OPM 24.6%, in range. New platform headwinds (OptraScan, Prognosys losses) will offset Truenat growth.

IPO funds already in hand. Breakdown detailed; facility in Bangalore. Minimal additional manufacturing capex needed.

OptraScan (60% stake, ₹30 Cr invested) unprofitable in FY27; management expects 'meaningful contribution' only in FY28–29. Integration risk, market adoption uncertain.

~90% of TB revenue from government public health programs. Policy shift, funding cuts, or transition to competing technology could materially impact revenue.

Export business only 3 years old; 16% of Q1 revenue (₹67 Cr). Management acknowledged past 'ups and downs'. Stabilizing now but early-stage.

Large capex program (₹200 Cr) will drain cash, reduce near-term profitability, and require flawless execution. Automation (₹72 Cr) and R&D centre (₹105+ Cr) are multi-year builds.

Device sales historically range 2,200–2,600 units/year. Q1 sales (164 units) are <10% of quarterly range, suggesting lumpiness. Management acknowledged Q4 typically strongest; guidance is annual, not quarterly.